COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.12% | -46.84% | -20.74% | 17.63% | -32.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.12% | -46.84% | -20.74% | 17.63% | -32.57% |
| Cost of Revenue | 7.56% | -9.11% | 2.63% | 16.93% | -11.71% |
| Gross Profit | 114.91% | -70.28% | -43.05% | 18.93% | -59.18% |
| SG&A Expenses | -46.78% | 279.63% | -29.78% | -13.37% | 52.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.29% | 45.70% | -46.82% | -16.25% | 4.52% |
| Operating Income | 72.55% | -607.01% | 56.91% | 37.34% | -46.58% |
| Income Before Tax | 93.16% | 61.53% | 69.00% | -42.41% | -47.49% |
| Income Tax Expenses | -- | -99.08% | -- | 100.21% | -- |
| Earnings from Continuing Operations | 93.16% | 67.57% | 68.39% | -89.94% | -90.86% |
| Earnings from Discontinued Operations | 1,215.19% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 394.31% | 67.57% | 68.39% | -89.94% | -160.89% |
| EBIT | 72.55% | -607.01% | 56.91% | 37.34% | -46.58% |
| EBITDA | 83.33% | -957.69% | 58.76% | 38.84% | -60.41% |
| EPS Basic | 394.65% | 36.09% | 69.10% | -32.82% | -53.30% |
| Normalized Basic EPS | 93.15% | -448.08% | 64.98% | 0.41% | 13.34% |
| EPS Diluted | 394.50% | 36.09% | 69.10% | -32.82% | -53.30% |
| Normalized Diluted EPS | 93.15% | -448.08% | 64.98% | 0.41% | 13.34% |
| Average Basic Shares Outstanding | -0.12% | 103.00% | 2.28% | 42.99% | 70.20% |
| Average Diluted Shares Outstanding | -0.12% | 103.00% | 2.28% | 42.99% | 70.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |